Logo Mark
Publications

Clinical Imetelstat: MDS

All Publications

Durable Continuous Transfusion Independence With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDSImetelstat
HOPA 2024

Platzbecker, et. al.

Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents

Clinical Imetelstat: MDSImetelstat
NCCN 2024

Madanat, et. al.

Patient-Reported Outcomes Among Heavily Pretreated Patients With Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated With Imetelstat in IMerge

Clinical Imetelstat: MDSImetelstat
Winter Heme 2024

Sekeres, et. al.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence Across Different Risk Subgroups in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents in IMerge Phase 3 Study

Clinical Imetelstat: MDSImetelstat
ASH 2023

Komrokji, et. al.

Impact of Mutational Status on Clinical Response to Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Clinical Imetelstat: MDSImetelstat
ASH 2023

Santini, et. al.

Durable Continuous Transfusion Independence (TI) With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDSImetelstat
ASH 2023

Platzbecker, et. al.

Imetelstat in patients with lower-risk MDS who have relapsed or are refractory to erythropoiesis-stimulating agents in IMerge phase 3 trial

Clinical Imetelstat: MDSImetelstat
The Lancet 2023

Platzbecker, et. al.

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents

Clinical Imetelstat: MDSImetelstat
AMCP Nexus 2023

Sekeres, et. al.

Telomerase-targeted therapies in myeloid malignancies

Clinical Imetelstat: MDSImetelstatNon-clinical ImetelstatNon-clinical Imetelstat: MF
Blood Advances 2023

Waksal, et. al.

Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Heavily Transfused Non-del (5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDSImetelstat
SOHO 2023

Sekeres, et. al